Combination therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies whether combining three treatments—an immunotherapy drug (Atezo), a blood-vessel-blocking drug (Bev), and a radioactive bead treatment (SIRT-Y90)—can help patients with advanced liver cancer that cannot be surgically removed. The goal is to see if using all three together works better than using fewer treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with unresectable hepatocellular carcinoma (advanced liver cancer that cannot be surgically removed)
- You have already received at least one dose of the combination therapy (Atezo + Bev) and completed at least one round of the radioactive bead treatment (SIRT-Y90)
- You have had at least one follow-up visit after starting these treatments
- You do not have any other active cancer diagnosis (except non-melanoma skin cancer)
- You are not enrolled in another experimental treatment study at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding a procedure called TACE to standard immunotherapy (Atezolizumab plus Bevacizumab) works better for people with liver cancer that cannot be removed by surgery. It aims to create a model to predict who benefits most from this combination.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This trial tests a new combination treatment: a radiation therapy called SIRT (given through a tube into the liver) plus an immunotherapy drug (atezolizumab, with or without bevacizumab). It is for people with advanced liver cancer that cannot be treated with surgery or other standard procedures.
This trial tests a combination of three treatments: an immunotherapy drug (Sintilimab), a targeted therapy (Bevacizumab), and a type of internal radiation (SIRT) for people with intermediate or advanced liver cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This phase 2 study tests whether adding immunotherapy drugs (atezolizumab and bevacizumab) after Y-90 treatment works better and is safe compared with Y-90 followed by placebo. It is for people with liver cancer that has not spread outside the liver but is difficult to treat.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.